VCEL$38.58
Chart
Performance
Key Stats
AI VCEL Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldVericel Corporation exhibits a mixed investment profile. While its financial health and profitability show recent improvements, the company's growth is moderate, and its valuation remains somewhat stretched. Technical indicators suggest a neutral to slightly bearish short-term outlook. The company operates in specialized biopharmaceutical markets, which carry inherent risks and rewards. Investors should consider the company's limited analyst coverage and the upcoming earnings report.
Thematic
Vericel operates in niche markets within sports medicine and severe burn care. Its core products like MACI and Epicel address specific medical needs. The company's growth potential is tied to the adoption and reimbursement of these advanced therapies. While these are important areas, they may not represent broad secular growth trends compared to larger technology or consumer themes.
Fundamental
Vericel has shown a positive turnaround in profitability, moving from losses to a net profit in the latest reported annual period. Revenue growth is present but not exceptionally strong. The company has managed its debt well, maintaining a reasonable debt-to-equity ratio and healthy cash reserves. Valuation metrics like P/E are high, especially given the moderate growth.
Technical
The stock price has experienced a significant decline over the past year, with the current price trading below key moving averages. Technical indicators like RSI and MACD suggest bearish momentum. However, there are some short-term signals that might indicate a potential for a temporary bounce or consolidation.
| Factor | Score |
|---|---|
| Biotechnology Advancements | 60 |
| Healthcare Market Growth | 50 |
| Niche Market Focus | 30 |
| Competitive Landscape | 50 |
| Regulatory Environment | 45 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 60 |
| Growth | 65 |
| Balance Sheet Health | 80 |
| Cash Flow | 40 |
| Factor | Score |
|---|---|
| Trend Analysis | 35 |
| Momentum | 40 |
| Volume Confirmation | 50 |
| Support & Resistance | 65 |
| MACD | 35 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive Free Cash Flow Trend
The company has shown a positive trend in free cash flow, with $7.798M in 2023 compared to -$5.811M in 2024, indicating improving cash generation capabilities.
Improving Profitability
The company has shifted from a net loss of -4.8% in 2021 to a net income of $10.362M (4.4% net margin) in 2024, demonstrating a significant turnaround in profitability.
Bearish Points (7)
Mixed Technical Signals
While some indicators show buy signals, many moving averages (e.g., Exponential Moving Average 10, 20, 30, 50, 100, 200 across various timeframes) show 'Sell' signals, indicating potential downward pressure.
High Price-to-Sales Ratio
The Price-to-Sales (PS) ratio is 10.0 for TTM and 11.7 for 2024, which is high, suggesting the stock might be overvalued relative to its sales.
Calendar
July 2025
31
Next Earnings Date
H: $-0.01
A: $-0.04
L: $-0.08
H: 65.05M
A: 64.49M
L: 62.94M
Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Seasonals
Price Target
58.12 USD
The 39 analysts offering 1 year price forecasts for VCEL have a max estimate of 67.00 and a min estimate of 49.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Direct strategic partner with Vericel for the commercialization of NexoBrid, an enzymatic debridement product for severe burns.
Weight: 98
Direct competitor in regenerative solutions for burns and wound care, notably with their RECELL System for skin regeneration.
Weight: 95
Direct competitor in the field of regenerative medicine, offering advanced wound care products and skin substitutes.
Weight: 92
Developing gene therapies for rare skin diseases, directly overlapping with Vericel's focus on skin regeneration and advanced therapies.